CMA1 and diabetic kidney disease: Since chymase expression increases in humans with diabetic nephropathy, studies were performed in leptin receptor‐deficient type 2 diabetic mice to test the hypothesis that chronic chymase inhibition reduces albuminuria and glomerular mesangial matrix and fibrosis.